// App-Quantinova.ai

1908 : Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment

Researchers

Presenter

  • Carter Thorne

Principal Investigators

  • Tsutomu Takeuchi

  • George Karpouzas

  • Shihong Sheng

  • Regina Kurrasch

  • Kaiyin Fei

  • Benjamin Hsu

Medical Centers

  • University of Toronto, Newmarket, Canada

  • Keio University Hospital School of Medicine, Tokyo, Japan

  • Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, United States

  • Janssen Research and Development, LLC, Spring House, PA

  • GlaxoSmithKline, Collegeville, PA

Locations

  • Canada

  • Japan

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Cytokine

  • Interleukin 6

Drug/Treatment

  • sirukumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved